The tobacco industry giant, Altria Group, has experienced a phase of volatile stock performance in recent quarters. While shareholders have celebrated periods of upward movement, the firm's outlook remain a topic of contention. Factors impacting Altria Group's stock comprise regulatory changes, market preferences, and the collective condition of th

The FDA has issued a warning about the risks of smuggled tirzepatide as the peptide therapeutics market grows rapidly. The market is expected to jump from $38 billion in 2023 to $106 billion by 2033, with an impressive 10.8% compound annual growth rate. Legitimate peptide medications have revolutionized modern medicine, with 102 FDA-approved therap